48 Stocks Moving In Friday’s Mid-Day Session
Gainers
Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday.
How To Attend Aldeyra Therapeutics Q1 2022 Earnings Conference Call
Aldeyra Therapeutics (NASDAQ:ALDX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Aldeyra Therapeutics CFO Joshua Reed To Resign; Bruce Greenberg Appointed Interim CFO
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to
Aldeyra Therapeutics Reports Completion Of Enrollment In Its Phase 3 TRANQUILITY-2 Trial In Patients With Dry Eye Disease
Top-Line Results from TRANQUILITY-2 Expected in the Second Quarter of 2022
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company discovering and developing
Aldeyra Therapeutics Reports Will Announce At Its 2022 R&D Day Tuesday 3 Of Its Trials Of ADX-629 Generated ‘signs of pharmacodynamic and clinical activity consistent with broad-based reduction in pathologic inflammation’
Signs of Pharmacodynamic and Clinical Activity Generated Across Three Phase 2 Proof-of-Concept Clinical Trials in Patients with Immune-Mediated Disease; No Safety or Tolerability Issues Observed
ADX-629 to Be Advanced
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.